scholarly journals Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiaomeng Feng ◽  
Jing Huang ◽  
Yan Peng ◽  
Yuan Xu

Abstract Background Serum uric acid (SUA) is associated with the development of diabetic kidney disease (DKD). Thyroid hormones can regulate metabolism and insulin resistance. The relationship between SUA and thyroid function in patients with DKD is still uncertain. In current study, we aimed to investigate the association between thyroid stimulating hormone (TSH) and SUA in type 2 diabetic patients with early-stage DKD. Methods Two hundred fifty-four type 2 diabetic patients with early-stage DKD were enrolled in current study and were further classified as high SUA group (SUA level > 420 μmol/L in males or > 360 μmol/L in females, n = 101) and normal SUA group (SUA level ≤ 420 μmol/L in males or ≤ 360 μmol/L in females, n = 153). Eighty-five control subjects were recruited as control group. The clinical characteristics were obtained via face-to-face surveys and medical records. Results Compared with normal SUA group and control group, high SUA group exhibited the increased SUA level, and the decreased TSH level (P < 0.017 for all), and no significant difference was detected in SUA and TSH between normal SUA group and control group. TSH was negatively associated with SUA (r = − 0.35, P < 0.001) in type 2 diabetic participants with early-stage DKD. Furthermore, the decreased TSH level was independently correlated with higher SUA level (β = − 25.69, P < 0.001), and retained a significant association with hyperuricemia (odds ratio = 1.73, P = 0.002) after adjusting for confounding factors in type 2 diabetic patients with early-stage DKD. Conclusions TSH is negatively correlated with SUA, and decreased TSH is an independent risk factor for hyperuricemia in type 2 diabetic patients with early-stage DKD. These results indicate that thyroid hormones, TSH in particular, might participate in regulating uric acid metabolism in patients with early-stage DKD.

2020 ◽  
Author(s):  
Xiaomeng Feng ◽  
Jing Huang ◽  
Yan Peng ◽  
Yuan Xu

Abstract Background Serum uric acid (SUA) is associated with the development of diabetic kidney disease (DKD). Thyroid hormones can regulate metabolism and insulin resistance. The relationship between SUA and thyroid function is still uncertain. Methods 254 type 2 diabetic patients with early-stage DKD were enrolled in current study and were further classified as high SUA group (SUA > 360 µmol/L, n = 126) and normal SUA group (SUA ≤ 360 µmol/L, n = 128). 85 control subjects were recruited as control group. The clinical characteristics were obtained via face-to-face surveys and medical records. Results Compared with normal SUA group and control group, high SUA group exhibited the increased SUA, free triiodothyronine and free thyroxine levels, and the decreased thyroid stimulating hormone (TSH) level (P < 0.017 for all), and no significant difference was detected in these parameters between normal SUA group and control group. Furthermore, the increased creatinine (β = 2.049, P < 0.001), triglycerides (β = 10.068, P < 0.001), urinary albumin-to-creatinine ratio (β = 0.262, P = 0.001), fasting blood glucose (β = 5.280, P = 0.003) and fasting insulin (β = 1.440, P = 0.034) levels, and the decreased TSH (β = -24.906, P < 0.001) level were independently correlated with higher SUA level in type 2 diabetic patients with early-stage DKD. Notably, decreased TSH retained a significant association (odds ratio = 1.654, P = 0.002) with hyperuricemia in type 2 diabetic patients with early-stage DKD. Conclusions TSH is negatively correlated with SUA, and decreased TSH is an independent risk factor for hyperuricemia in type 2 diabetic patients with early-stage DKD. These results indicate that thyroid hormones, TSH in particular, might participate in regulating uric acid metabolism in patients with early-stage DKD.


2004 ◽  
Vol 287 (3) ◽  
pp. H1225-H1231 ◽  
Author(s):  
Lucilla D. Monti ◽  
Claudio Landoni ◽  
Emanuela Setola ◽  
Elena Galluccio ◽  
Pietro Lucotti ◽  
...  

We evaluated the influence of chronic hypertriglyceridemia and endothelial dysfunction on myocardial glucose uptake (MGU) in Type 2 diabetic patients without coronary heart disease. Patients were divided into two groups according to fasting triglyceride (TG) levels: 5.4 ± 1.1 and 1.5 ± 0.3 mmol/l for high- and normal-TG groups, respectively. Five subjects were assigned to the high-TG group and 11 to the normal-TG group. Age, gender, body mass index, systolic and diastolic blood pressure, glucose, insulin, HbA1c, cholesterol, and HDL cholesterol were similar in the two groups, whereas free fatty acid (FFA) levels were higher in the high-TG group basally and at the end of the clamp. Furthermore, five healthy subjects were subjected to the same protocol and used as the control group. MGU was assessed by using 18F-labeled 2-fluoro-2-deoxy-d-glucose under hyperglycemic-hyperinsulinemic conditions. Basal endothelin-1 and nitric oxide levels were significantly higher in the high-TG group than in the normal-TG and control groups, and cGMP and maximal postischemic vasodilation were significantly decreased in the high-TG group compared with the normal-TG and control groups. However, significant alterations were found in the same parameters in the normal-TG group compared with the control group. By the end of the hyperglycemic clamp, in the high-TG group, MGU was ∼40 and 65% of that in the normal-TG and control groups. MGU negatively correlated with TG, FFA, and endothelin-1, whereas a positive correlation was found with cGMP and maximal postischemic vasodilation. In conclusion, increased TG and FFA levels are risks, in addition to Type 2 diabetes mellitus, for myocardial insulin resistance, endothelial dysfunction, and alteration of nitric oxide/cGMP levels.


2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Lei Feng ◽  
Changqing Deng ◽  
Yanxia Li

Objective. This study aimed to explore the associations between carotid intima-media thickness (CIMT) and early-stage diabetic kidney disease (DKD) coupled with Helicobacter pylori (H. pylori) infection in type 2 diabetic patients. Methods. A cross-sectional study including 180 type 2 diabetic participants was conducted to explore the associations between CIMT and early-stage DKD coupled with H. pylori infection, and a stepwise multivariate regression analysis evaluated the correlations of CIMT with clinical and serologic parameters. Results. The type 2 diabetic patients with early-stage DKD coupled with H. pylori infections had the highest CIMT values. Apolipoprotein B (ApoB), urine albumin/creatinine ratio (UACR), and interleukin-6 (IL-6) were independent predictors of CIMT. Conclusions. Early-stage DKD coupled with H. pylori infection may synergistically lead to significant CIMT thickening in type 2 diabetic patients. Additionally, ApoB, UACR, and IL-6 levels were important independent risk factors for increased CIMT.


2016 ◽  
Vol 40 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Roksana Yeasmin ◽  
MA Muttalib ◽  
Naznin Sultana ◽  
Nizamul Hoque Bhuiyan ◽  
Rashedul Alam

Investigation of the serum level of copper, zinc, magnesium and manganese in type-2 diabetes mellitus and their possible association with lipid profile was carried out. The comparative study included 100 type-2 diabetic patients in Gr-II and 100 non-diabetic as control in (Gr-I). Results indicated that there is a significant lower level (p < .001) of serum Zn, Cu, Mg and Mn in diabetic patients compared with the control group, showing p value < .001. In type-2 DM patients (Gr-II) there were significant correlations between serum Zn and TAG (r = 0.209) and between Zn and HDL-C level (r = .199) showing p value <.05. Non significant relationships were found in between Zn and lipid profile (TAG, Cholesterol, HDL-C and LDL-C) of control (Gr-I) group. Significant correlation was found between serum magnesium and TAG of control (Gr-I) where p < .01 and non significant correlations were found in serum Mg and total cholesterol, HDL-C, LDL-C of both type-2 diabetic (Gr-II) and control (Gr-I). Significant correlations were also found in between serum of Cu and Mn and TAG of control (Gr-I) where p < .05 and non significant correlations were found in other component of lipid profile of both cases (Gr-II) and control (Gr-I).Journal of Bangladesh Academy of Sciences, Vol. 40, No. 1, 79-85, 2016


2011 ◽  
Vol 119 (08) ◽  
pp. 497-501 ◽  
Author(s):  
M. Chon ◽  
J. Suk ◽  
K. Oh ◽  
K. Kim ◽  
Y. Kim ◽  
...  

AbstractStatins have marked beneficial effects on lipid profile, but also have pleiotropic actions. A previous study in an iodine-deficient area suggested that statin use is associated with reduced thyroid volume and nodularity. We performed this study to investigate how long-term statin use in type 2 diabetic patients affects thyroid nodularity in iodine-sufficient area.We recruited euthyroid type 2 diabetic patients, receiving statin therapy continuously for at least 5 years (statin group) and, age and sex matched statin-naive type 2 diabetic patients (control group). Subjects with past history of cancer, thyroid disease or treatment with lithium or amiodarone; family history of thyroid cancer; palpable goiter or thyroid nodule, and/or positive thyroperoxidase antibody were excluded. The prevalence, number, and volume of thyroid nodules, size of thyroid were evaluated in all subjects by high resolution ultrasound.Prevalence of non-palpable thyroid nodules of statin group (n=70) and control group (n=98) were 51 and 53% , respectively. There was no difference of prevalence, number, and volume of non-palpable thyroid nodules and size of thyroid between statin and control group. But, the patients aged between 60 and 65 years from statin group showed lower prevalence of non-palpable thyroid nodules than the patients with same age interval from control group (4 out of 12 patients, 33% , statin group; 19 out of 27 patients, 70% , control group; P=0.04).Long-term statin use in elderly type 2 diabetic patients was associated with lesser prevalence of thyroid nodules in an iodine-sufficient area. Our data might support a possible antiproliferative effect of statins on thyroid in old type 2 diabetic patients. But, the effect was not as strong as that in an iodine-deficient area and further studies with enough numbers of subjects and revised design will be needed.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 539-P
Author(s):  
YOSHINORI KAKUTANI ◽  
MASANORI EMOTO ◽  
KATSUHITO MORI ◽  
YUKO YAMAZAKI ◽  
AKINOBU OCHI ◽  
...  

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Magdy EL Sharkawy ◽  
Samir K Abdul-Hamid ◽  
Tarek T Elmelegy ◽  
Mohammed F Adawy

Abstract Background Diabetes mellitus (DM) is the most frequent cause of chronic kidney failure in both developed and developing countries. Diabetic nephropathy, is a clinical syndrome characterized by albuminuria (&gt;300 mg/day) with permanent and irreversible decrease in glomerular filtration rate (GFR). Aim of the Work To study the role of urinary TNF-α and urine KIM-1 in type 2 diabetic patients as predictors of DN comparative with albuminuria. Patients and Methods This is a cross-sectional study which include 90 type-2 diabetic patients and 30 controls selected from the outpatient clinic of Assiut University hospitals. All patients gave an informed consent and approval for the study was obtained from the IRB committee of the Assiut Medical Faculty. The recruited patients were divided into three groups: Normo-albuminuria Group (A) (n = 30): UACR less than 30 mg/gm, Microalbuminuria Group (B) (n = 30): UACR between 30-299 mg/gm and Macro-albuminuria Group (C) (n = 30): UACR equal or more than 300 mg/gm. Assess Urinary TNF-α and urine KIM-1 in comparision with albuminuria. Results Urinary KIM-1 and urinary TNF-α are statically significant with albuminuria in patients in the early stage of diabetic nephropathy (eGFR _60 mL/min/1.73 m2).Also there are statically significance between patients with macroalbuminuria than microalbuminuria. Conclusion The results of this study recommend the use of KIM-1 and TNF-α as good predictors of early detection of development of diabetic nephropathy.


Background: Adiponectin is a collagen-like plasma protein secreted by adipocytes that has been suggested to play a causal role in the development of insulin resistance. Even though hypoadiponectinaemia is reported to be closely associated with obesity-related diseases such as ACVD, type 2 DM, dyslipidaemia, report from our environment is lacking. Materials and Methods: Serum adiponectin, insulin and glucose were measured in 90 type 2 diabetic and control subjects respectively. The patients were known diabetics attending the diabetic clinic at the ABUTH, Zaria. The control subjects were apparently healthy individuals within the hospital and Zaria environs. Results: Mean serum adiponectin levels were significantly lower (P<0.05) in the diabetic patients than in the control subjects. On the other hand, the mean values of insulin and glucose were significantly higher (P<0.05) in the diabetic patients than in the controls. Conclusion: Measurement of serum adiponectin as an adjunct in the biochemical assessment of type 2 DM is suggested.


2021 ◽  
Author(s):  
Mercan Taştemur ◽  
Selvihan Beysel ◽  
Sema Hepşen ◽  
Sanem Öztekin ◽  
Erman Çakal ◽  
...  

Background: This study aims to investigate the role of ADAMTS7 and ADAMTS12 on atherosclerosis and inflammation in prediabetic and diabetic patients. Patients & methods: Serum ADAMTS7 and ADAMTS12 levels were compared with the atherosclerotic and inflammatory markers in diabetic (n = 65, female 30.9%, mean age = 53 years), prediabetic (n = 55, female 36.6%, mean age = 49 years) and control groups (n = 55, females 32.5%, mean age = 49 years). Serum ADAMTS levels were determined by a human enzyme-liked immunoassay. Results: In terms of ADAMTS7, there was no significant difference between diabetic, prediabetic and control groups (50.93, 44.34, 59.07, respectively; p > 0.05). ADAMTS12 is lower in diabetics (p < 0.05), whereas it is similar in prediabetics and controls (14.53, 20.76, 25.05, respectively; p > 0.05). ADAMTS7 and ADAMTS12 levels did not differ in diabetic nephropathy, retinopathy and neuropathy (p > 0.05). Conclusion: While ADAMTS12 was significantly lower in diabetics and prediabetics, ADAMTS7 and ADAMTS12 were not related to diabetic complications (nephropathy, retinopathy and neuropathy).


Sign in / Sign up

Export Citation Format

Share Document